VANCOUVER, BC / ACCESSWIRE / August 25, 2020 / Voice Mobility International, Inc. (the "Company") (TSXV:VMY.H) announces that it has entered into a letter of intent (the "LOI") dated effective August 24th, 2020 outlining the general terms and conditions with respect to the acquisition (the "Acquisition") by the Company of all the issued and outstanding share capital of Myco Sciences Limited ("MyCo").

The Company and MyCo are at arms-length, and the Acquisition of MyCo will constitute a reverse-takeover of the Company in accordance with the policies of the TSX Venture Exchange (the "Exchange"). Assuming completion of the Acquisition, it is anticipated that the Company will be listed on the Exchange as a Tier 2 Technology Issuer.

MyCo has developed and patented a solubilised copper zinc ammonium complex that appears to kill pathogenic fungi in plants directly while also potentially triggering a plant's immune system to defend itself against further fungi attack. In 2016 and 2017, the results of which were delivered in 2019 and 2020, MyCo, in collaboration with the research team at Exeter University, was granted two Industrial Partnership awards with the Research Council BBSRC in the United Kingdom worth over £1.67 million. MyCo is currently in discussions with a major North American Research University to further research and develop its technology in the next two years with the end goal of commercialization applicable to the entire plant-based agricultural industry.

As of March 31, 2020, MyCo has spent £608,901 (approximately CAD$1,065,577) primarily on research and development and patent costs. MyCo has accounted £53,847 (approximately CAD$94,232) in net losses from April 1, 2019 to March 31, 2020. As at March 31, 2020, MyCo had net assets of £99,766 (approximately CAD$174,591), and total current liabilities of £6,857 (approximately CAD$12,000). These numbers are taken from MyCo's unaudited financial statements of March 31, 2020 as filed at Companies House in the UK.

MyCo was incorporated in the United Kingdom as a private limited company on May 27th, 2014.

Further financial information relating to MyCo will be released when available.

Terms of the Acquisition

MyCo is a privately held company existing under the laws of the United Kingdom. MyCo currently has 4,076 common shares ("MyCo Shares") issued and outstanding. Insiders of MyCo collectively control 70.34% of the outstanding MyCo Shares. Chris Wightman, Founder and Executive Chairman, and Stephen Chandler, an investor, control 1,260 (30.91%) and 1,097 (26.91%) of the outstanding MyCo Shares, respectively.

Under the terms of the Acquisition, the Company will complete a share consolidation on a twenty-four-for-one basis (the "Consolidation"), and shareholders of MyCo will be issued post-Consolidation common shares of the Company (the "Consideration Shares") in exchange for MyCo Shares on a 3,557.4092 for 1 basis. This will result in the issuance of 14,500,000 Consideration Shares based on the current capital structure of MyCo. Certain of the Consideration Shares will be subject to escrow pursuant to the policies of the Exchange, in addition to pooling restrictions that may be negotiated by the parties.

Following completion of the Acquisition, it is anticipated that the shareholders of MyCo will own a significant majority of the outstanding common shares of the Company. It is also anticipated that the Company will change its name in connection with completion of the Acquisition.

Financing

As a condition to completing the Acquisition, the parties intend to complete a non-brokered private placement financing (the "Financing") to raise up to US$4,500,000 through the issuance of up to 4,500,000 subscription receipts at US$1.00 per subscription receipt. The pricing of the Financing was determined in the context of the market. The proceeds of the Financing will be held in escrow, pending the Company receiving all applicable regulatory approvals, completing the share consolidation described above and completing the Acquisition. Upon satisfaction of the escrow conditions, each subscription receipt will automatically convert into one post-Consolidation common share of the Company for no additional consideration. If the Acquisition is not completed on or before December 31, 2020, the Financing proceeds will be returned to the subscribers. Finder's fees may be payable to arm's length parties who introduce the Company to subscribers, in accordance with the policies of the Exchange.

In addition, MyCo will complete an additional share issuance (the "MyCo Financing") during the interim period pending closing of the Acquisition to raise capital necessary for transaction expenses and advancement of MyCo's business. These shares will also be exchanged for Consideration Shares in the same ratio as the existing MyCo Shares.

Upon Closing of the Acquisition and Financing, the resulting issuer will have 21,400,000 post consolidated common shares issued and outstanding.

Board of Directors and Management Changes

On completion of the proposed Acquisition, the Company's board of directors and management team will be reconstituted to consist of four directors determined by MyCo, including the individuals listed below. Information on additional board and management appointments, including the Chief Financial Officer and Corporate Secretary, will be disclosed when available.

Dave Arnold, CEO and Director

Mr. Arnold's career has been as a senior executive and venture entrepreneur with publicly listed and private companies operating in multiple technology sectors, principally serving international markets. He is currently founder and CEO of Vibrant Global Ventures Limited, a private company incorporated in Hong Kong with the aim of founding and building early stage technology companies. Dave began his career in 1983 with Burlington Northern Inc., a NYSE listed Fortune 100 transportation and energy resources company based in Seattle. He worked on the USD $1.4 billion acquisition of NYSE listed El Paso Natural Gas Pipeline Company and USD $900 million merger with NYSE listed Southland Royalty Company, was promoted to Senior Corporate Planner, then to Vice President and Chief Financial Officer of BNI's telecommunications subsidiary, National Exchange Inc. In 1988 he joined Pacific Northern Inc., a private oil distribution company, as Vice President Finance, then became President and CEO and Director, expanding sales four-fold to USD $265 million in 65 countries, mainly to major shipping companies. In 1995 Mr. Arnold joined Intermind Corporation, a private software company, as Chief Operating Officer, then became CEO and Director, raising equity capital and establishing an IP base of patents in internet privacy, completing commercial products for personalized information interchange with 170 corporate partners. In 1998 he joined N2H2 Inc., a NASDAQ listed software company as Chief Operating Officer after its IPO, negotiating international marketing partnerships and with the share price increasing 3.9 times during his tenure. Dave joined eFund LLC, a venture capital company in 2000, first as Venture Partner, then became Managing Director, negotiating several multiplayer game company acquisitions in Asia for a portfolio company, Mforma Group Inc. He also served as its CFO and Director, and as President and GM, Asia, raising for Mforma USD $84 million equity at a USD $260 million pre-money valuation, resulting in a 4.1x venture fund ROI during his tenure. Mr. Arnold holds an undergraduate degree from Cornell University as a College Scholar, and MBA degree in general management from the Amos Tuck School of Business at Dartmouth College.

Chris Wightman, Director

Mr. Wightman was an investment banker with Goldman Sachs (Head of Risk, Europe), Bankers Trust (Equity Derivatives), NatWest Markets (Founder, CEO NatWest Financial Products) and BankAmerica (NationsBank Head of Global Equities). Subsequent to his Investment Banking career, Mr. Wightman became a serial entrepreneur focused on broad technology themes. Amongst other ongoing businesses, in 1997 he founded what became PuriCore, a business developing the chemistry behind the mammalian immune system (HOCl). As Executive Chairman, he listed it on the full list of the London Stock Exchange in 2006. Work there included a successful UK grant programme investigation of the application for HOCl in agriculture, and the filing of a number of patents reflecting the novel formulations discovered. The team who led the studies (then) at Oxford University, now at Exeter University, requested that Chris consider the potential for a Copper/Zinc/Phosphite chemistry in 2014. The result is MyCo Sciences.

Michael Sapountzoglou, non-Executive Chairman

Mr. Sapountzoglou's principal career has been primarily in shipping corporate finance, direct private equity and capital markets. He is currently co-founder and CEO of Bluewater Acquisition Corp., a public company incorporated in Canada with the aim of raising capital for shipping investments. He began his career with the G.S Livanos shipping group, in Athens and subsequently in their Monaco family office focusing on trading and asset management. In 1994 he joined the Angelopoulos Group at their family office in London and Athens where he held various senior positions in groups investments within the group until his departure in 2015. He led projects within the group's core investments including steel, shipping, yacht building – through the ownership of Oceanco and off- shore UDW rigs. As Finance Director for Metrostar Management Corp., he led the company's shipping financing strategy and business development. In the offshore drilling sector, he was director of Deepsea Metro, a joint venture with Odfjell Drilling Ltd. Where he co-led the company's fundraising efforts, raising over $1.5 billion in the capital markets. He has held various non-executive directorships and following the Group's major investment in PuriCore, he was also a Director from 1999-2013 and chaired the Remuneration and Nomination committees. Mr. Sapountzoglou resides in Athens, was raised in Toronto, is a Canadian citizen and holds an Honors BA in Economics and International Finance from Wilfrid Laurier University in Canada.

Closing of the Acquisition

Closing of the Acquisition is subject to a number of conditions including the satisfactory completion of due diligence, the negotiation and entering into of definitive agreements, the completion of the Consolidation, the redomiciling of the Company's jurisdiction of incorporation from the State of Nevada to the Province of British Columbia, the completion of the Financing, receipt of all required shareholder, regulatory and third-party consents, including Exchange approval, and satisfaction of other customary closing conditions. The Acquisition and Financing cannot close until the required approvals are obtained. There can be no assurance that the Acquisition and Financing will be completed as proposed or at all. Except in connection with the Financing, no finders' fees or commissions are payable in connection with completion of the Acquisition.

Shareholder Approval

Approval of the shareholders of the Company will not be required in connection with the Acquisition, in accordance with Exchange Policy 5.2, as the Acquisition is not a related party transaction and no other circumstances exist which may compromise the independence of the Company or other interested parties. The Company is without active operations, is not subject to a cease trade order or trading suspension, and shareholder approval is not required for the Acquisition under applicable corporate or securities laws. The Company does intend to seek shareholder approval for the Consolidation, the redomiciling of its jurisdiction of incorporation and the reconstitution of its board of directors.

Sponsorship

Sponsorship of the Acquisition is required by Exchange Policy 2.2, unless an exemption from the sponsorship requirement is available. The Company will be seeking a waiver of any requirement for a sponsor in connection with the Acquisition.

Trading in the common shares of the Company will remain halted pending further filings with the Exchange.

FOR MORE INFORMATION PLEASE CONTACT:

VOICE MOBILITY INTERNATIONAL INC.
Scott Ackerman
Email: sackerman@emprisecapital.com
Telephone: (778) 331 8505

The TSX Venture Exchange has in no way passed upon the merits of the proposed Acquisition and has neither approved nor disapproved the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Completion of the Acquisition is subject to a number of conditions, including but not limited to Exchange acceptance and shareholder approval, if applicable. The Acquisition and Financing cannot be completed until such approvals are obtained. There can be no assurance that the Acquisition will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the filing statement to be prepared in connection with the Acquisition, any information released or received with respect to the Acquisition may not be accurate or complete and should not be relied upon. Trading in the securities of the Company should be considered highly speculative.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as, "forward‐looking statements". Forward‐looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward‐looking statements, including without limitation those relating to the Company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward‐looking statements.

SOURCE: Voice Mobility International, Inc.

ReleaseID: 603267

Unique to the Cannabis Industry, Item 9 Labs' Cocktails Line Offers Bar-Goers All The Taste Without The Bar, Ideal for the Current COVID-19 Pandemic Environment

PHOENIX, AZ / ACCESSWIRE / August 25, 2020 / Item 9 Labs Corp. (OTCQB:INLB) ("Item 9 Labs" or the "Company"), a vertically integrated cannabis operator that produces premium products, is celebrating the one-year anniversary of their industry-first Cocktails vaporization pens with the release of three new Summer Series flavors.

The Cocktails Summer Series release features Margarita, Mimosa, and Sangria – joining mainstays Blackberry Mojito, Old Fashioned, No Laws: Hard Soda, Piña Colada, and Strawberry Daiquiri.

Cocktails – featuring rechargeable, disposable pens flavored like popular drinks – are created by blending organically grown terpenes with distilled Delta 9 THC produced in-house. Available in 300mg all-in-one devices, they're geared toward on-the-go patients looking for options that don't require separate batteries or special hardware.

Initially developed as a way to bring familiar tastes into adult-use cannabis markets for weekender moments and celebrations with friends, Cocktails' ever-increasing flavors have led to a sales surge as patients flock to them, seeking a bridge between alcohol and cannabis consumption – without worrying about mixing the two.

"The Summer Series has received an overwhelmingly positive response among patients and bud tenders alike – the new flavors are easily a favorite of theirs across the Cocktails line," Item 9 Labs Vice President of Marketing Kyle Jennings said.

"Arizona patients are always looking for something new, and the simplicity of the Cocktails line allows us to deliver hit after hit each holiday season or special occasion," Jennings added, noting that the Company has also released seasonal flavors alongside Christmas, Fat Tuesday, and St. Patrick's Day.

Beyond the debut of the Summer Series, Item 9 Labs commemorated the one-year anniversary by offering a "Staycation" contest through a partnership with Territory, an Arizona dispensary. Winners will be announced soon for a $500 gift certificate to Sanctuary Camelback Mountain Resort that can be used at their restaurant, spa, or hotel rooms or a $250 voucher good toward Item 9 Labs products at Territory.

The initial Summer Series run will be available throughout the third quarter and may be added to the permanent Cocktails lineup if demand for the flavors remains high.

About Item 9 Labs Corp.

Item 9 Labs Corp. (OTCQB: INLB) is a vertically integrated multi-state cannabis operator headquartered in Arizona. The Company creates best-in-class products and canna-business solutions designed to help people become the best versions of themselves. With an award-winning CPG brand and nationally recognized application team, Item 9 Labs improves the cannabis experience while providing transparency, consistency, and well-being for those relying on them. For additional information, please visit: item9labscorp.com.

Media Contact:

Item 9 Labs
Jayne Levy, Director of Communications
Email: Jayne@unityrd.com

Investor Contact:

Hayden IR
Brett Mass, Managing Partner
Phone: (646) 536-7331
Email: INLB@haydenir.com

SOURCE: Item 9 Labs Corp.

ReleaseID: 603010

REDWOOD CITY, CA / ACCESSWIRE / August 25, 2020 / Avinger, Inc. (NASAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the closing of an underwritten public offering of 11,063,830 shares of its common stock at a price of $0.47 per share, for total gross proceeds of approximately $5.2 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,000,000 shares of common stock to cover over-allotments, if any, at the public offering price. The shares were offered pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (SEC). A prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC and are available on the SEC's website at www.sec.gov.

Aegis Capital Corp. acted as sole bookrunner for the offering.

A copy of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained by contacting Aegis Capital Corp., Attention: Prospectus Department, 810 7th Avenue, 18th floor, New York, NY 10019, by email at syndicate@aegiscap.com, or by telephone at (212) 813-1010.This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

About Avinger, Inc.

Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.

Investor Contact:

Mark Weinswig
Chief Financial Officer
Avinger, Inc.
(650) 241-7916
ir@avinger.com

Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200

Safe Harbor Disclosure

This press release includes statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements related to the option granted by the Company's to the underwriters and other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond our control, include: the effects of the COVID-19 pandemic on our operations and general economic conditions; risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of development activities; our ability to attract, integrate and retain key personnel; our need for substantial additional funds; patent and intellectual property matters; competition; as well as other risks described in the section entitled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the SEC on March 6, 2020 and in our other filings with the SEC, including, without limitation, our reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

SOURCE: Avinger, Inc.

ReleaseID: 603226

PORTLAND, OR / ACCESSWIRE / August 25, 2020 / Today, LeadsRx, a marketing attribution company, introduced David Canelis as a new member of the executive team in the newly created position of Vice President of Customer Success.

In his new role Canelis will lead the LeadsRx Customer Success team in developing industry best practices and establish processes to ensure customers excel in their use of LeadsRx Attribution.

"LeadsRx has made great strides in establishing marketing attribution as an essential data-science tool that marketers around the world are adopting at an increasing rate," said David Canelis, VP of Customer Success at LeadsRx. "I look forward to expanding and establishing customer success methodologies and practices to help marketers excel in their use of marketing attribution to maximize return on ad spend even in a most challenging economic climate."

Canelis is regarded as a customer success, services, and support expert with more than 20 years of experience in building and leading customer success programs for technology companies including Tableau Software, WebTrends, Oracle, among others.

"LeadsRx business is growing exponentially in North America and internationally and it's important to have someone of David's experience to build out LeadsRx enterprise-class customer success programs and professional services," said AJ Brown, co-founder and CEO of LeadsRx. "David's expertise in creating customer success programs will set a new industry standard for adoption and use of marketing attribution by marketing agencies and enterprise brands and help them get the most return on ad spend and derive more revenue from sales."

For more on LeadsRx Attribution software visit LeadsRx.com.

# # #

About LeadsRx

A fast innovator and a marketer's choice for 4,000-plus global and local brands, LeadsRx is an unrivaled multi-touch attribution SaaS platform. Powered by a unique Universal Conversion Tracking Pixel™, LeadsRx provides an impartial view of customer journeys, giving each advertising touchpoint proper weight and credit including broadcast media. Founded by marketers, LeadsRx enables companies of any size to elevate marketing performance in a framework that is easily understood delivering sustainable return on ad spend (ROAS). To learn more about how LeadsRx can support you in marketing transformation visit LeadsRx.com. Connect with LeadsRx on Twitter, LinkedIn and Facebook.

For more information

Jeff Fishburn
Fishburn PR for LeadsRx
+1 (503) 799-1988
jeff@fishburnpr.com

SOURCE: LeadsRx

ReleaseID: 603259

Celebrating the Start of Construction for its Commercial Lithium-Ion Battery Recycling Pilot Plant

INCLINE VILLAGE, NV / ACCESSWIRE / August 25, 2020 / American Battery Metals Corporation (OTCQB:ABML) (the "Company"), an American-owned lithium-ion battery recycling technology and advanced extraction company with extensive mineral resources in Nevada, is pleased to announce the scheduling of its ground breaking ceremony for its commercial lithium-ion battery recycling pilot plant for Thursday, August 27. The ceremony celebrating the start of construction will begin at 2 pm at 345 Winston Lane in Fernley, Nevada.

GROUNDBREAKING CEREMONY
Thursday, August 27 at 2 pm
345 Winston Lane, Fernley, Nevada

Doug Cole, Chief Executive Officer of American Battery Metals Corporation, commented, "This event has been a long time coming as our team has put a lot of hard work to get to this point. We are extremely excited for this ground breaking and the work ahead of us to get the plant operational. We will be joined by local government officials who have really supported our efforts and champion our vision for lithium-ion battery recycling and clean sustainable energy. If you would like to join us at the ground breaking, please contact Katie Baker, our Corporate Communications leader, at 925-330-4450."

American Battery Metals Corporation
American Battery Metals Corporation (www.batterymetals.com) (OTCQB:ABML) is an American-owned lithium-ion battery recycling technology and advanced extraction company with extensive mineral resources in Nevada. The company is focused on its lithium-ion battery recycling and resource production projects in Nevada, with the goal of becoming a substantial domestic supplier of battery metals to the rapidly growing electric vehicle and battery storage markets.

For more information, please visit: www.batterymetals.com

Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including those with respect to the expected project economics for Western Nevada Basin (Railroad Valley), including estimates of life of mine, average production, cash costs, AISC, initial CAPEX, sustaining CAPEX, pre-tax IRR, pre-tax NPV, net cash flows and recovery rates, the impact of self-mining versus contract mining, the timing to obtain necessary permits, the submission of the project for final investment approval and the timing of initial gold production after investment approval and full financing, metallurgy and processing expectations, the mineral resource estimate, expectations regarding the ability to expand the mineral resource through future drilling, ongoing work to be conducted at the Western Nevada Basin (Railroad Valley), and the potential results of such efforts, the potential commissioning of a Pre-Feasibility study and the effects on timing of the project, are "forward-looking statements." Although the Company's management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve a number of risks and uncertainties, which could cause the Company's future results to differ materially from those anticipated. Potential risks and uncertainties include, among others, interpretations or reinterpretations of geologic information, unfavorable exploration results, inability to obtain permits required for future exploration, development or production, general economic conditions and conditions affecting the industries in which the Company operates; the uncertainty of regulatory requirements and approvals; fluctuating mineral and commodity prices, final investment approval and the ability to obtain necessary financing on acceptable terms or at all. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended September 30, 2019. The Company assumes no obligation to update any of the information contained or referenced in this press release.

Contact Information
P:775-473-4744
info@batterymetals.com

SOURCE: American Battery Metals Corporation

ReleaseID: 603179

Adult category relaunch forecasted to generate annual sales of over $2,000,000

MediaCentral commits to increase its support for sex workers leveraging advertising and editorial opportunities surrounding sex positivity

TORONTO, ON / ACCESSWIRE / August 25, 2020 / Media Central Corporation Inc. (CSE:FLYY)(FSE:3AT) ("MediaCentral" or the "Company") today announced that its wholly owned Toronto-based media brand NOW Magazine has joined its sibling publication, Vancouver's Georgia Straight ("the Straight") in re-launching the sale of adult classifieds. The highly lucrative category is forecasted to add significant revenue growth to the Company with an expected combined annual revenue of over $2,000,000.

"Prior to eliminating adult advertising, NOW generated strong sales from its Adult Classifieds Category. The Straight has continued to offer adult advertising over the years, but the category was temporarily suspended during the height of COVID," said CEO Brian Kalish. "Now that the two respective cities have begun reopening, we expect this re-launch to drive strong sales numbers alongside our newly revamped and fully integrated sales platforms. Our decision to bring back the classifieds is part of our strategic path to creating sustainable, profitable publications."

In addition to the adult classifieds, both publications will continue to use their award-winning editorial platforms to highlight and share stories around sex positivity, adult entertainment, and the rights of sex workers. NOW continues to share trending stories and features through its LOVE & SEX category and readers of both NOW and the Straight enjoy sagely advice via the popular syndicated column Savage Love by Dan Savage.

"NOW has always supported diverse sexual choice, the LGBTQ+ community and the rights of sex workers," said Kevin Ritchie, Editor of NOW Magazine. "In 2018, we stopped offering classifieds in the adult entertainment category because of stifling provincial legislation. This year, Ontario Justice Thomas McKay struck down the ban on advertising sexual services, again allowing sex workers a right to promote their services. This development further reinforces our ability to provide a voice to those living alternative lifestyles and who have a right to the freedom of expression."

-END-

About Media Central Corporation Inc.

Media Central Corporation Inc. (CSE: FLYY, FSE: 3AT) is an alternative media company situated to acquire and develop high-quality publishing assets starting with the recent acquisition of Vancouver Free Press Publishing Corp., the purchase of NOW Communications Inc. and the launch of digital cannabis platform CannCentral.com and esports destination ECentralSports.com. MediaCentral is consolidating and digitally monetizing the over 100 million coveted and premium consumers of the approximately 100 alternative urban publications across North America, creating the most powerful audience of influencers.

www.mediacentralcorp.com
Instagram: @mediacentralcorp
Twitter: @mediacentralc
Facebook: Media Central Corp.

About Vancouver Free Press Publishing Corp., Vancouver Free Press Publishing Corp., owns and operates Georgia Straight and straight.com. Established in 1967 as the news, lifestyle, and entertainment weekly in Vancouver, the Georgia Straight has been an integral part of the active urban West Coast lifestyle for over 50 years. Reaching over 56 million annual readers, every Thursday in print, and every day at straight.com, Georgia Straight delivers an award-winning editorial package of features, articles, and reviews. Regular coverage includes news, tech, arts, music, fashion, travel, health, cannabis, and food, plus Vancouver's most comprehensive listings of entertainment activities and special events. Vancouver Free Press Corp. is a wholly owned subsidiary of Media Central Corporation Inc. (CSE: FLYY, FSE: 3AT).

www.straight.com
Instagram: @georgiastraight
Twitter: @georgiastraight
Facebook: @georgiastraight

About NOW Central Communications Inc.

NOW Central owns and operates NOW Magazine and nowtoronto.com. Since 1981 NOW has been Toronto's news and entertainment voice, published in print every Thursday, and daily at nowtoronto.com. Reaching over 25 million annual readers, NOW has been a leading publication, defining and pioneering the independent and alternative voice for more than 38 years. NOW Central Communications Inc. is a wholly owned subsidiary of Media Central Corporation Inc. (CSE: FLYY, FSE: 3AT).

www.nowtoronto.com
Instagram: @nowtoronto
Twitter: @nowtoronto
Facebook: facebook.com/nowmagazine

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release may include, but are not limited to, statements with respect to internal expectations, expectations with respect to estimated margins, cost structures, and cost structures in the media industry. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the media industry generally, income tax and regulatory matters; the ability of MediaCentral to implement its business strategies; competition; currency and interest rate fluctuations and other risks.

Readers are cautioned that the foregoing list is not exhaustive and should carefully review the various risks and uncertainties identified in the Company's filings on SEDAR. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

For further information:

Investor Relations:
Investors@mediacentralcorp.com

Media:
Faulhaber Communications, Lexi Pathak, media@mediacentralcorp.com

www.mediacentralcorp.com

SOURCE: Media Central Corporation Inc.

ReleaseID: 603035

CALGARY, AB / ACCESSWIRE / August 25, 2020 / CANEX Metals Inc. (TSXV:CANX) ("CANEX" or the "Company") is pleased to announce that drilling has commenced at the Gold Range Property, Arizona.

Drilling has commenced at Gold Range with the first hole expected to be completed by the end of the day. Drilling is initially targeting the Pit Zone where 62 previously released chip and grab samples ranged from trace to 48 g/t gold, averaging 8.5 g/t gold. The drill program will consist of approximately 1675 metres (5500 feet) of reverse circulation drilling designed to test up to 7 different targets with multiple holes per target. The targets being tested with this maiden round of drilling occur over a 2 kilometre by 4 kilometre area and all contain gold mineralization exposed at surface.

The drill program is expected to take up to 25 days to complete. Samples will be sent for assay in multiple shipments as the program progresses to help expedite initial sample results.

Exploration Update

Field personnel have been on site since early July conducting surface exploration and mapping activities focusing on expanding existing zones and discovering new zones of gold mineralization. Multiple new gold exploration targets have been identified and are being advanced to define new drill targets for future testing. Over 100 rock and 214 soil samples have been collected from these targets and submitted for assay.

A single geophysical test line of induced polarization – resistivity has been completed at Gold Range. A second test line was cancelled due to high fire risk. Final results from the completed test line are expected in the next few weeks.

About the Gold Range Property

The Gold Range Property is located in Northern Arizona within an area that has seen historic lode and placer gold production but limited systematic modern lode gold exploration. Fieldwork by the Company has identified numerous gold exploration targets on the property with grab samples from outcropping quartz veins returning multiple values in the 20 to 40 g/t gold range, and chip sampling returning values of 53.2 g/t gold over 0.6 metres, 31.7 g/t gold over 1 metre, 24.3 g/t gold over 1.5 metres, 28.1 g/t gold over 1 metre, 17.2 g/t over 1.1 metre, and 8.47 g/t gold over 5.6 metres. Please visit our website at www.canexmetals.ca for additionnel information.

Dr. Shane Ebert P.Geo., is the Qualified Person for CANEX Metals and has approved the technical disclosure contained in this news release.

"Shane Ebert",

Shane Ebert
President/Director

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Except for the historical and present factual information contained herein, the matters set forth in this news release, including words such as "expects", "projects", "plans", "anticipates" and similar expressions, are forward-looking information that represents management of CANEX Metals Inc. internal projections, expectations or beliefs concerning, among other things, future operating results and various components thereof or the economic performance of CANEX. The projections, estimates and beliefs contained in such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause CANEX's actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things, those described in CANEX's filings with the Canadian securities authorities. Accordingly, holders of CANEX shares and potential investors are cautioned that events or circumstances could cause results to differ materially from those predicted. CANEX disclaims any responsibility to update these forward-looking statements.

SOURCE: CANEX Metals Inc.

ReleaseID: 603166

Two of Five Patients Enrolled for the Study

IRVINE, CA / ACCESSWIRE / August 25, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has enrolled the first two patients for its first-in-human CoreoGraft study. The first implant of the CoreoGraft conduits will take place in the coming weeks and HJLI will announce the schedule when available. The first-in-human trial will consist of up to 5 patients.

Interim results for patients in the CoreoGraft study, which will take place at Italian Hospital Asuncion in Paraguay, will be available 30 days, 90 days, 180 days, and 365 days post-surgery. CoreoGrafts will be implanted in patients requiring coronary artery bypass grafting ("CABG") for severe coronary artery diseases. The 3 mm CoreoGraft conduit is being used as a substitute for saphenous vein grafts in these patients. Saphenous vein grafts are known to have high short-term and long-term failure rates. Once the CoreoGrafts are implanted, they will be evaluated at each interval of the follow-up period for signs of failure including "openness" or "patency", blood clots ("thrombus") and other changes commonly associated with graft failure.

Robert Berman, Hancock Jaffe's CEO stated, "We have several upcoming milestones to be excited about including the beginning of our first-in-human trial for the CoreoGraft, the conclusion of our first-in-human trial for the VenoValve, and preparations for the VenoValve U.S. pivotal trial. We believe that the combination of our clinical advancements together with the steps we are taking to position the company for long term success, will continue to add to our momentum through the remainder of 2020 and beyond."

In January of 2020, HJLI released positive results from its six (6) month CoreoGraft animal feasibility study. At thirty (30), ninety (90), and one hundred and eighty (180) days post CoreoGraft bypass surgeries, all grafts we patent (open), when the implantations went smoothly and there were no technical errors. At the conclusion of the study, pathology examinations of the grafts and surrounding tissue showed no signs of thrombosis, infection, aneurysmal degeneration, changes in the lumen, or other problems that are known to plague saphenous vein grafts ("SVGs"). In addition, the pathology examinations indicated a thin layer of endothelial cells in the CoreoGrafts that were implanted for 90 days, and more complete endothelization was observed for grafts implanted for 180 days both throughout the CoreoGrafts and into the left anterior descending arteries. Endothelialization is thought to be a critical step in establishing the long-term biocompatibility of cardiovascular devices.

For patients with suitable veins, the current standard of care for most CABG surgeries is to harvest the saphenous vein from the leg of the patient, dissect the SVGs into multiple grafts, and to use the dissected grafts to revascularize the heart. In addition to the vein harvest procedure being invasive, painful, and subject to its own complications for the patient, SVGs are also known to have high short term and long-term failure rates when used as grafts around the heart. Studies indicate that up to 40% of SVGs fail within one year of CABG surgeries, with a significant percentage failing within the first 30 days. Eight to ten years after surgery, SVG failure rates are known to be in as high as 75%. Eventually, the CoreoGraft could become a viable alternative to using SVGs.

Approximately 200,000 CABG surgeries are performed each year in the U.S., representing more than 55% of all cardiac surgeries and accounting for between $15 Billion and $25 Billion in annual expenditures. With an average of three grafts used per surgery, HJLI estimates the potential U.S. addressable market for the CoreoGraft to be more than $2 Billion per year. There are currently no FDA approved prosthetic grafts for CABG surgeries. The Company will provide periodic updates on additional patient enrollment and dates for surgeries once they are available.

About Hancock Jaffe Laboratories, Inc.

HJLI specializes in developing and manufacturing bioprosthetic (tissue based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency; and the CoreoGraftÒ, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery. For more information, please visit HancockJaffe.com.

Cautionary Note on Forward-Looking Statements

This press release and any statements of stockholders, directors, employees, representatives and partners of Hancock Jaffe Laboratories, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results (including, without limitation, with respect to our first-in-human VenoValve study) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

HJLI Press Contacts:

Amy Carmer
Tel: 949-261-2900
Email: ACarmer@HancockJaffe.com

SOURCE: Hancock Jaffe Laboratories, Inc.

ReleaseID: 603180